Lykera Biomed S.A. is developing antibodies against S100 proteins that play roles in multiple processes and cell types that enable tumor growth and progression. The company expects its antibodies will be more efficacious than a more advanced small molecule inhibitor of an S100 protein.

According to CSO Francesc Mitjans, Lykera was founded by a team of former Serono S.A. employees who moved to the not-for-profit Leitat Technological Center after Merck KGaA acquired Serono and shuttered its Barcelona site in 2007. At Leitat, the team developed antibodies against novel cancer targets, and then spun out the technology into Lykera.